Data

A multicentre single arm study to evaluate the safety and efficacy of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (TE NDMM) patients refractory to initial bortezomib-based induction therapy (MM17)

Health Data Australia Contributor Records
Spencer, Andrew ; Australasian Leukaemia And Lymphoma Group (ALLG) ; Australasian Leukaemia And Lymphoma Group (ALLG)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/FPTH-DX17&rft.title=A multicentre single arm study to evaluate the safety and efficacy of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (TE NDMM) patients refractory to initial bortezomib-based induction therapy (MM17)&rft.identifier=http://doi.org/10.58109/FPTH-DX17&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=Dataset includes: Data for 50 patients with newly diagnosed, transplant eligible, multiple myeloma using carfilzomib-thalidomide-dexamethasone (CarTD), in a randomised trial Demographic data, diagnostic data, treatment data, outcome data&rft.creator=Spencer, Andrew &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12615000934549&rft_subject=Chemotherapy&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

Dataset includes: Data for 50 patients with newly diagnosed, transplant eligible, multiple myeloma using carfilzomib-thalidomide-dexamethasone (CarTD), in a randomised trial Demographic data, diagnostic data, treatment data, outcome data

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Subjects
Chemotherapy |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

doi : https://doi.org/10.1182/blood-2021-152034

Australasian Leukaemia And Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Identifiers
Similar data you may be interested in: